Clinical review of thyroid malignant tumor.

Acta Otolaryngol Suppl

Department of Otorhinolaryngology. Kitasato University, School of Medicine, Kanagawa, Japan.

Published: January 2003

We reviewed the files of 120 patients with thyroid malignant tumor treated in our department between July 1971 and December 1996. Clinical features, pathological diagnosis, radiographic findings, treatment and prognosis were studied. The number of patients treated gradually increased over time in both the otorhinolaryngology and surgery departments. Papillary carcinoma (n = 101) was the most common pathology, followed by follicular carcinoma (n = 16). Both 5- and 10-year survival rates were 92.7% for the entire group, 93.8% for cases of follicular carcinoma and 92.1% for cases of papillary carcinoma. Although thyroid tumor is undoubtedly one of the malignant head and neck tumors associated with an excellent prognosis, some patients remain resistant to cure in the long term. Some tumors are highly malignant and are difficult to control. The management of these patients is an important subject of future research.

Download full-text PDF

Source
http://dx.doi.org/10.1080/000164802760057653DOI Listing

Publication Analysis

Top Keywords

thyroid malignant
8
malignant tumor
8
papillary carcinoma
8
follicular carcinoma
8
clinical review
4
review thyroid
4
malignant
4
tumor reviewed
4
reviewed files
4
files 120
4

Similar Publications

Vulvar lichen planus a retrospective analysis.

Arch Dermatol Res

January 2025

Department of Dermatology and Venereal Diseases, Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.

Vulvar lichen planus (VLP) is a rare mucocutaneous disorder with significant impacts on quality of life and a potential risk of malignancy. Comprehensive data on its clinical features and treatment outcomes remain limited. To analyze the demographic and clinical characteristics of patients diagnosed with VLP and to evaluate the efficacy of current therapeutic approaches.

View Article and Find Full Text PDF

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Cancer Commun (Lond)

January 2025

Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.

Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.

Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.

View Article and Find Full Text PDF

Relationship of modifiable risk factors with the incidence of thyroid cancer: a worldwide study.

BMC Res Notes

January 2025

Non-Communicable Diseases Research Center, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Background: Thyroid cancer is one of the most common cancers of the endocrine system. The incidence of this cancer has increased in many countries. Many cases of thyroid cancer do not have any symptoms.

View Article and Find Full Text PDF

Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignancy with a poor prognosis. Therefore, early diagnosis and treatment are critical to the survival of patients and to improve their quality of life. However, diagnosing this illness is challenging.

View Article and Find Full Text PDF

Introduction Thyroid malignancy remains a significant global health concern, making the accurate differentiation between benign and malignant thyroid nodules crucial for optimal patient management. Fine-needle aspiration cytology (FNAC) is the gold-standard preoperative diagnostic tool, and The Bethesda System for Reporting Thyroid Cytopathology provides a standardized framework for interpretation. This 10-year retrospective study evaluated the malignancy risk in surgically treated patients with thyroid nodules classified as Bethesda Category III by comparing FNAC findings with histopathological outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!